Skip to content

Jazz Pharmaceuticals JAZZ Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations

Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations at other companies

RB Global logo
RB GlobalRBA
$1.6M+12.3%
Blackstone logo
BlackstoneBX
$33.9M+16.5%
Evercore logo
EvercoreEVR
$313K+566%
SBA Communications logo
SBA CommunicationsSBAC
$89.75K+124%
Baxter International logo
Baxter InternationalBAX
$64.5M+5,060%
SBA Communications logo
SBA CommunicationsSBAC
$89.75K+124%

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$14.11B+54.4%
Enterprise value$18.85B+47.7%
P/S3.2×+0.9×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations.

The official record: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about Jazz Pharmaceuticals's unrecognized tax benefits reductions resulting from lapse of applicable statute of limitations.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Jazz Pharmaceuticals's unrecognized tax benefits reductions resulting from lapse of applicable statute of limitations?
Jazz Pharmaceuticals (JAZZ) reported unrecognized tax benefits reductions resulting from lapse of applicable statute of limitations of $6.68M in Q4 2025.
How has Jazz Pharmaceuticals's unrecognized tax benefits reductions resulting from lapse of applicable statute of limitations changed year-over-year?
Jazz Pharmaceuticals's unrecognized tax benefits reductions resulting from lapse of applicable statute of limitations increased by 0.7% year-over-year, from $6.63M to $6.68M.
What is the long-term trend for Jazz Pharmaceuticals's unrecognized tax benefits reductions resulting from lapse of applicable statute of limitations?
Over 4 years (2021 to 2025), Jazz Pharmaceuticals's unrecognized tax benefits reductions resulting from lapse of applicable statute of limitations has grown at a 0.1% compound annual growth rate (CAGR), from $26.57M to $26.71M.
What does unrecognized tax benefits reductions resulting from lapse of applicable statute of limitations mean?
The reduction in tax uncertainty because the time limit for tax authorities to audit a position has passed.
How do you interpret unrecognized tax benefits reductions resulting from lapse of applicable statute of limitations?
This is a positive indicator as it represents the permanent removal of tax risk without the need for cash settlement.
How does unrecognized tax benefits reductions resulting from lapse of applicable statute of limitations compare across companies?
A standard, non-cash benefit to the effective tax rate that is common across all tax-paying entities.